Durham, NC, United States
Durham, NC, United States

Time filter

Source Type

News Article | May 9, 2017
Site: www.businesswire.com

TOKYO--(BUSINESS WIRE)--JSR Life Sciences (JLS), the global life sciences focused division of JSR Corporation, today announced plans for expansion of its production capabilities of AmsphereTM A3 protein-A chromatography resin at JSR’s Belgium subsidiary, JSR Micro NV. This expansion will effectively increase the company's production capacity by 6 times and provide all-important redundancy in its manufacturing capability. JLS’ AmsphereTM A3 has experienced rapid adoption as an alkali-stable, high-capacity alternative option for downstream purification in the biopharmaceutical industry since its launch in January 2016. Based on that success and growing demand, JLS has implemented a business continuity strategy that includes multiple location manufacturing to ensure both critical material supply to the global biopharmaceutical market and additional scale capabilities. JSR chose to expand in Belgium because of the extensive biochemistry and ligand manufacturing expertise already in place at JSR Micro NV as well as the significance of the European market. Phase one of the expansion construction started earlier this year with plans to be fully operational in 2018. The multi-phased expansion plan will keep pace with the growing demand for JLS’s AmsphereTM A3, with the total additional capacity completed by the end of the company’s fiscal year 2019. In 2015, JSR acquired a majority interest in contract development and manufacturing organization KBI Biopharma, Inc., a well-established leader in contract development and manufacturing of biopharmaceutical products, with an extensive track record of successful programs for its clients. JLS credits KBI Biopharma with playing a large role in the success of AmsphereTM A3 that lead to this expansion plan. “The product development evolution of our protein A resin and the success of AmsphereTM A3 could not have been possible without the development expertise of KBI Biopharma,” said Eric Johnson, President of JSR’s Life Sciences Division (JLS). “KBI has provided not only a testing ground, but also a leadership that is critical to our success. We are thrilled with the positive market response our AmsphereTM resin has received and look forward to continuing to work with KBI as we move into our next phases and extend and widen our biopharma process technologies product portfolio.” AmsphereTM A3 is a high capacity resin with overall improved process robustness, flow characteristics, optimized impurity removal, productivity and resin lifetime. JLS launched its first Protein A chromatography media in 2012 and has since focused on leveraging JSR Corporation’s core competency in advanced polymer chemistry coupled with JLS’ expertise in protein ligand design and conjugation. As a result, AmsphereTM A3 is uniquely designed to purify monoclonal antibodies using an innovative polymer matrix and proprietary ligand technology. JSR Life Sciences Division is a business unit of JSR Corporation, which provides specialized materials and products to the biotech industry. JSR Life Sciences operates a network of manufacturing facilities, sales offices and R&D labs in key markets throughout North America, Europe and Asia-Pacific. JSR Life Sciences today is focused on diagnostics and research products and downstream bioprocessing materials for pharmaceutical manufacturing.


News Article | May 9, 2017
Site: www.businesswire.com

JSR a décidé de s'étendre en Belgique en raison de l'expertise étendue en matière de biochimie et de fabrication de ligands d'ores et déjà en place chez JSR Micro NV, ainsi que de l'importance du marché européen. La première phase des travaux d'expansion a débuté plus tôt cette année, et le projet est d'atteindre une pleine opérationnalité d'ici 2018. Le projet d'expansion en plusieurs étapes restera en phase avec la demande croissante relative à AmsphereTM A3 de JLS, et la capacité supplémentaire totale devrait être achevée d'ici la fin de l'exercice 2019 de la société. En 2015, JSR a acquis une participation majoritaire dans l'organisation de développement et de fabrication sous contrat KBI Biopharma, Inc., leader bien établi dans le développement et la fabrication sous contrat de produits biopharmaceutiques, qui est largement renommé pour la réussite de ses programmes destinés à ses clients. JLS considère comme important le rôle que KBI Biopharma joue dans le succès d'AmsphereTM A3, et qui a contribué à ce projet d'expansion. « L'évolution du développement produit de notre résine de protéine A et le succès d'AmsphereTM A3 n'auraient pas été possibles sans l'expertise de développement de KBI Biopharma », a déclaré Eric Johnson, président de la division JSR Life Sciences (JLS). « KBI nous a non seulement fourni un terrain d'essai, mais également le leadership qui est indispensable à notre succès. Nous sommes enchantés par la réponse positive du marché qu'a suscitée notre résine AmsphereTM, et nous sommes impatients de poursuivre nos travaux avec KBI à l'heure où nous entamons de nouvelles phases, tout en étendant et élargissant notre gamme de produits axés sur les technologies de processus biopharmaceutiques. » AmsphereTM A3 est une résine de haute capacité offrant amélioration de la robustesse des processus, caractéristiques de flux, retrait optimisé des impuretés, productivité et durée de vie de la résine. JLS a lancé son support de chromatographie de la protéine A en 2012, et se focalise depuis sur l'exploitation de la compétence clé de JSR Corporation en matière de chimie avancée des polymères, associée à l'expertise de JLS en matière de conception et de conjugaison de ligands protéiques. Par conséquent, AmsphereTM A3 est conçu de manière unique pour purifier les anticorps monoclonaux en utilisant une matrice de polymères innovante ainsi qu'une technologie de ligands brevetée. La division JSR Life Sciences est une unité commerciale de JSR Corporation qui fournit des matériaux et des produits spécialisés au secteur biotechnologique. JSR Life Sciences exploite un réseau d'installations de fabrication, des bureaux de vente ainsi que des laboratoires de R&D dans plusieurs marchés clés répartis à travers l'Amérique du Nord, l'Europe et l'Asie-Pacifique. JSR Life Sciences se focalise aujourd'hui sur les produits de diagnostic et de recherche, ainsi que sur les matériaux de biotraitement en aval pour la fabrication pharmaceutique.


News Article | May 9, 2017
Site: www.businesswire.com

Im Jahr 2015 erwarb JSR die Mehrheitsbeteiligung an der Vertragsentwicklungs- und Produktionsorganisation KBI Biopharma, Inc., einem etablierten Marktführer in der Auftragsentwicklung und -herstellung von biopharmazeutischen Produkten, mit einer umfangreichen Erfolgsbilanz erfolgreicher Programme für seine Kunden. JLS kreditiert KBI Biopharma mit einer großen Rolle beim Erfolg von AmsphereTM A3, die zu diesem Erweiterungsplan geführt hat.


News Article | May 16, 2017
Site: globenewswire.com

Dublin, May 16, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Lyophilization Services for Biopharmaceuticals, 2017-2027" report to their offering. The Lyophilization Services for Biopharmaceuticals, 2017-2027' report provides an extensive study on the current market landscape of lyophilization services for biopharmaceuticals. The study presents an in-depth analysis of a diverse set of companies that provide such services across different regions worldwide. In fact, we identified close to 90 companies that are actively involved in providing lyophilization services for biopharmaceuticals. The study features a detailed analysis of the existing size and potential future growth opportunities (2017-2027) in the lyophilization services market for biopharmaceuticals. We have provided insights on the likely regional evolution of the market covering North America, Europe (UK, France, Italy, Spain, Germany and rest of Europe), Asia Pacific (Japan, China, India and South Korea) and rest of the world. In addition, we have provided the likely evolution and a market attractiveness analysis on the basis of the type of containment system (bulk containers, vials, syringes, ampoules and cartridges). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have presented three different forecast scenarios, depicting conservative, base and optimistic tracks of the market's evolution. The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzed from publicly available data. For the purpose of the study, we invited over 80 stakeholders to participate in a survey to solicit their opinions on upcoming opportunities, challenges and likely future trends. The opinions and insights presented in this study were also influenced by discussions conducted with experts in this field. These included contributions from Steven Nail (Principal Scientist, Baxter BioPharma Solutions), Adam Viverette (Lyophilization Manager, Patheon), Patrick DePalma (Director, CMO Business Development, BioDefense Division, Emergent BioSolutions) and John Shaw (Head of Business Development and Marketing, Vibalogics). Key Topics Covered: 1. PREFACE 1.1. Scope of the Report 1.2. Research Methodology 1.3. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION TO LYOPHILIZATION 3.1. Chapter Overview 3.2. Lyophilization: Historical Background 3.3. Lyophilization: Underlying Principle 3.4. Lyophilization: Equipment 3.5. Lyophilization: Advantages and Disadvantages 3.6. Lyophilization: Applications 4. LYOPHILIZATION OF BIOPHARMACEUTICALS 4.1. Chapter Overview 4.2. Need for Lyophilization of Biopharmaceuticals 4.3. Lyophilization Process for Biopharmaceuticals 4.4. Lyophilization Cycle Development and Optimization 4.5. Containment Systems Used for the Lyophilization of Biopharmaceuticals 5. COMPETITIVE LANDSCAPE 5.1. Chapter Overview 5.2. Lyophilization Service Providers for Biopharmaceuticals: Overall Landscape 5.3. Lyophilization Service Providers for Biopharmaceuticals: Analysis by Type of Biopharmaceuticals Lyophilized 5.4. Lyophilization Service Provides for Biopharmaceuticals: Analysis by Scale of Operation 5.5. Lyophilization Service Providers for Biopharmaceuticals: Analysis by Containment Systems 6. LYOPHILIZATION SERVICE PROVIDERS FOR BIOPHARMACEUTICALS: NORTH AMERICA 6.1. Chapter Overview 6.2. Anteco Pharma 6.3. Axcellerate Pharma 6.4. Berkshire Sterile Manufacturing 6.5. Emergent BioSolutions 6.6. LSNE Contract Manufacturing 6.7. Lyophilization Technology 6.8. Quality BioResources 6.9. North America: Lyophilization Services Market for Biopharmaceuticals, 2017-2027 (USD Million) 7. LYOPHILIZATION SERVICE PROVIDERS FOR BIOPHARMACEUTICALS: EUROPE 7.1. Chapter Overview 7.2. Amatsigroup 7.3. Biopharma Technology 7.4. Boehringer Ingelheim BioXcellence 7.5. LYOCONTRACT 7.6. Lyofal 7.7. Vetter Pharma 7.8. Europe: Lyophilization Services Market for Biopharmaceuticals, 2017-2027 (USD Million) 8. LYOPHILIZATION SERVICE PROVIDERS FOR BIOPHARMACEUTICALS: ASIA PACIFIC 8.1. Chapter Overview 8.2. BioZed Engineering 8.3. Bovogen Biologics 8.4. CinnaGen 8.5. Mycenax Biotech 8.6. Piramal Pharma Solutions 8.7. Samsung Biologics 8.8. Siam Bioscience 8.9. WuXi AppTec 8.10. Asia Pacific: Lyophilization Services Market for Biopharmaceuticals, 2017-2027 (USD Million) 8.10.1. Asia Pacific Lyophilization Services Market for Biopharmaceuticals: Distribution by Type of Containment System (USD Million) 9. MARKET SIZING AND FORECAST 9.1. Chapter Overview 9.2. Forecast Methodology 9.3. Lyophilization Services Market for Biopharmaceuticals, 2017-2027 (USD Million) 9.4. Lyophilization Services Market for Biopharmaceuticals, 2017-2027: Distribution by Region (USD Million) 9.5. Lyophilization Services Market for Biopharmaceuticals, 2017-2027: Distribution by Type of Containment System (USD Million) 10. BENCHMARK ANALYSIS 10.1. Chapter Overview 10.2. Benchmark Analysis: Methodology 10.3. Benchmark Analysis: Peer Groups 11. LYOPHILIZATION CYCLE DEVELOPMENT AND OPTIMIZATION 11.1. Chapter Overview 11.2. Lyophilization Cycle Development 11.3. Lyophilization Cycle Optimization 11.4. Lyophilization Cycle Development and Optimization: Service Providers 11.5. Lyophilization Cycle Development and Optimization Service Providers: Company Snapshots 12. ALTERNATIVE APPROACHES TO LYOPHILIZATION 12.1. Chapter Overview 12.2. Spray Drying 12.3. Spray Freeze Drying 12.4. Atmospheric Spray Freeze Drying 12.5. Vacuum Foam Drying 13. SURVEY ANALYSIS 13.1. Chapter Overview 13.2. Seniority Level of Respondents 13.3. Type of Biopharmaceuticals Lyophilized 13.4. Type of Containment System 13.5. Scale of Operation 13.6. Lyophilization Cycle Development and Optimization 13.7. Location of Lyophilization Facility 13.8. Likely Market Size 14. CONCLUSION 14.1. In Light of High Costs Associated with Establishing In-house Lyophilization Capabilities, Outsourcing has Emerged as a Convenient Alternative 14.2. Cycle Development and Optimization are Among the Key Lyophilization Processes; a Number of Players Specializing in These Services Have Entered the Market Expanding the Value Chain 14.3. Although Alternative Methods have Gained Attention in Recent Times, Lyophilization will Continue to Play a Pivotal Role 14.4. Fueled by the Growing Pipeline of Biopharmaceuticals, the Market is Likely to Witness Continuous Growth in the Coming Decade 15. INTERVIEW TRANSCRIPTS 15.1. Chapter Overview 15.2. Steven Nail, Principal Scientist, Baxter BioPharma Solutions 15.3. Adam Viverette, Lyophilization Manager, Patheon 15.4. Patrick DePalma, Director, CMO Business Development BioDefense Division, Emergent BioSolutions 15.5. John Shaw, Head of Business Development and Marketing, Vibalogics Companies Mentioned - AB BioTechnologies - Affinity Biologicals - Affinity Life Sciences - Ajinomoto - Albany Molecular Research (AMRI) - Alcami - Althea - Amatsigroup - Anteco Pharma - Apexigen - Aptevo Therapeutics - AusiaBio - Avrio Biopharmaceuticals - Axcellerate Pharma - Axys-Network - BSP Pharmaceuticals - Baccinex - Baxter BioPharma Solutions - Bayer Healthcare - Berkshire Sterile Manufacturing (BSM) - BioConnection - BioReliance - BioTechLogic - BioTechnique - BioZed Engineering - Biocon - Biopharma Technology - Bioserv Corporation - Biotechpharma - Biovian - Boehringer Ingelheim BioXcellence - Bovogen Biologicals - Bryllan - Burrard Pharmaceuticals - CARBOGEN AMCIS - CEPiA - CMC Biologics - Camurus - Canada Peptide - Capua BioServices - Catalent - Cenexi - CinnaGen - Clarity BioSolutions - Cobra Biologics - Coldstream Laboratories - Cook Pharmica - Corden Pharma - Coriolis Pharma - CuriRx - Dalton Pharma Services - DavosPharma - EUCODIS Bioscience - Emergent BioSolutions - Engineered Biopharmaceuticals - Eurogentec - FUJIFILM Diosynth Biotechnologies - Famar Health Care Services - Fedegari Group - Formurex - Fresenius Kabi Product Partnering - Frontage Labs - GILYOS (GIeseler LYOphilization Solutions) - GP Pharm - Gipharma - GlaxoSmithKline (GSK) - Goodwin Biotechnology - Grand River Aseptic Manufacturing (GRAM) - HALIX - HTD Biosystems - Hart Biologicals - Hovione - Hycult Biotech - IDIFARMA - IDT Biologika - Infectious Disease Research Institute (IDRI) - Integrity Bio - Jubilant HollisterStier - Jubilant Pharma - KABS Pharmaceutical Services - KBI Biopharma - Kamat Pharmatech - Kemwell Biopharma - LEUKOCARE - LSNE Contract Manufacturing - LYOCONTRACT - Legacy BioDesign - Lonza - Lyofal - Lyophilization Technology - MabPlex - Markt Technologies - MassDevelopment - Medicago - Micro-sphere - Miltenyi Biotec - Mycenax Biotech - NanoTools - National Institute of Allergy and Infectious Diseases (NIAID) - Nitto Avecia Pharma Services - Nova Laboratories - OctoPlus - Oncotec Pharma Produktion - OsoBio - PREMAS Biotech - PYRAMID Laboratories - PaizaBio - Particle Sciences - Patheon - Pfizer CentreOne - Pharmagen - Pharmatek - Pierre Fabre - Piramal Pharma Solutions - Praxair - Praxis Pharmaceutical - ProJect Pharmaceutics - Quality BioResources - Recipharm - Rentschler - SGS Group - SP Scientific - SYNERLAB Group - Samsung Biologics - Sanofi - Siam Bioscience - Singota Solutions - StemProtein - Symbiosis Pharmaceutical Services - SynCo Bio Partners - Syngene - The Native Antigen Company (NAC) - Therapure Biomanufacturing - Tofflon - Universal Stabilization Technologies - Upperton - Vectura - Vetter Pharma - Vibalogics - VxP Pharma - Wolfe Laboratories - WuXi AppTec For more information about this report visit http://www.researchandmarkets.com/research/46rmjf/lyophilization

Loading KBI Biopharma collaborators
Loading KBI Biopharma collaborators